Sluggishness adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 9,986 adverse event reports that record the MedDRA preferred term Sluggishness. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 517 reports in the 12 months to June 2026 and 469 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 968 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 517 (under 0.1%) record this term. Reports for patients aged 45 to 64 were 24.6% of the reports that record this term and 20% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 98 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Sluggishness name as a suspect product, in order of name
Drug	Class	Reports with this term
Abilify	Atypical antipsychotic	67
Actemra	Interleukin-6 receptor antagonist	26
Adempas	Soluble guanylate cyclase stimulator	29
Alcohol		32
Alprazolam	Benzodiazepine	43
Ambrisentan	Endothelin receptor antagonist	32
Amlodipine	Calcium channel blocker	26
Ampyra	Potassium channel blocker	60
Androgel		26
Aripiprazole	Atypical antipsychotic	32
Avonex	Interferon beta	140
Byetta	GLP-1 receptor agonist	63
Cabometyx	Kinase inhibitor	30
Carbidopa levodopa	Aromatic amino acid	33
Chantix	Partial cholinergic nicotinic agonist	60
Clonazepam	Benzodiazepine	44
Cosentyx	Interleukin-17A antagonist	70
Cymbalta		70
Depakin		32
Diazepam	Benzodiazepine	38
Duodopa		31
Dupixent	Interleukin-4 receptor alpha antagonist	90
Eliquis	Factor Xa inhibitor	35
Enbrel	Tumor necrosis factor blocker	208
Entresto	Angiotensin 2 receptor blocker	213
Escitalopram	Serotonin reuptake inhibitor	26
Forteo	Parathyroid hormone analog	109
Gabapentin	Anti-epileptic agent	52
Gilenya	Sphingosine 1-phosphate receptor modulator	116
Haldol		142
Humalog	Insulin analog	41
Humira		273
Ibrance	Kinase inhibitor	47
Imbruvica	Kinase inhibitor	37
Ingrezza	Vesicular monoamine transporter 2 inhibitor	48
Invega	Atypical antipsychotic	57
Invega Sustenna	Atypical antipsychotic	28
Jakafi	Janus kinase inhibitor	58
Kesimpta	CD20-directed cytolytic antibody	89
Kisqali	Kinase inhibitor	59
Lamictal	Anti-epileptic agent	26
Letairis	Endothelin receptor antagonist	29
Levothyroxine		47
Lipitor	HMG-CoA reductase inhibitor	25
Lorazepam	Benzodiazepine	74
Lyrica		117
Methotrexate	Folate analog metabolic inhibitor	33
Metoprolol	beta-Adrenergic blocker	53
Mounjaro	GLP-1 receptor agonist	47
Nuplazid	Atypical antipsychotic	76
Ocrevus	CD20-directed cytolytic antibody	63
Olanzapine	Atypical antipsychotic	46
Opsumit	Endothelin receptor antagonist	62
Orenitram	Prostacycline vasodilator	35
Orgovyx	Gonadotropin releasing hormone receptor antagonist	71
Otezla	Phosphodiesterase 4 inhibitor	40
Ozempic	GLP-1 receptor agonist	68
Pegasys	Interferon alpha	60
Pomalyst	Thalidomide analog	34
Prednisone	Corticosteroid	39
Quetiapine	Atypical antipsychotic	70
Remicade	Tumor necrosis factor blocker	26
Remodulin	Prostacycline vasodilator	53
Repatha	PCSK9 inhibitor	86
Revlimid	Thalidomide analog	131
Ribavirin	Nucleoside analog antiviral	51
Risperdal	Atypical antipsychotic	247
Risperidone	Atypical antipsychotic	43
Rivotril		73
Rytary	Aromatic amino acid	31
Sandostatin LAR Depot		48
Seroquel	Atypical antipsychotic	74
Skyrizi	Interleukin-23 antagonist	32
Soliris	Complement inhibitor	43
Strattera	Norepinephrine reuptake inhibitor	27
Sutent	Kinase inhibitor	35
Synthroid	l-Thyroxine	84
Tavor		27
Tecfidera		56
Tegretol	Mood stabilizer	32
Topamax		83
Trulicity	GLP-1 receptor agonist	58
Tymlos		28
Tysabri	Integrin receptor antagonist	312
Tyvaso	Prostacycline vasodilator	26
Uptravi	Prostacyclin receptor agonist	34
Valium	Benzodiazepine	26
Venlafaxine	Serotonin and norepinephrine reuptake inhibitor	25
Vivitrol		30
Vyvanse	Central nervous system stimulant	27
Xanax	Benzodiazepine	65
Xeljanz	Janus kinase inhibitor	54
Xolair	Anti-IgE	32
Xtandi	Androgen receptor inhibitor	42
Xyrem	Central nervous system depressant	119
Zoloft	Serotonin reuptake inhibitor	32
Zopiclone		29
Zyprexa	Atypical antipsychotic	40

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 42 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Sluggishness name, in order of name
Class	Reports with this term
Androgen receptor inhibitor	61
Angiotensin 2 receptor blocker	300
Anti-epileptic agent	161
Aromatic amino acid	79
Atypical antipsychotic	863
Benzodiazepine	305
beta-Adrenergic blocker	141
CD20-directed cytolytic antibody	180
Central nervous system depressant	161
Central nervous system stimulant	66
Complement inhibitor	69
Corticosteroid	92
Endothelin receptor antagonist	132
GLP-1 receptor agonist	284
Gonadotropin releasing hormone receptor antagonist	71
Histamine-1 receptor antagonist	61
HMG-CoA reductase inhibitor	55
Insulin analog	120
Integrin receptor antagonist	329
Interferon alpha	60
Interferon beta	166
Interleukin-17A antagonist	70
Interleukin-4 receptor alpha antagonist	92
Janus kinase inhibitor	136
Kinase inhibitor	309
l-Thyroxine	130
Mood stabilizer	67
Nonsteroidal anti-inflammatory drug	57
Nucleoside analog antiviral	51
Opioid agonist	95
Parathyroid hormone analog	113
Partial cholinergic nicotinic agonist	60
PCSK9 inhibitor	97
Potassium channel blocker	65
Prostacycline vasodilator	176
Proton pump inhibitor	51
Serotonin and norepinephrine reuptake inhibitor	86
Serotonin reuptake inhibitor	196
Sphingosine 1-phosphate receptor modulator	125
Thalidomide analog	179
Tumor necrosis factor blocker	280
Vesicular monoamine transporter 2 inhibitor	52

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Sluggishness, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Sluggishness
Age	Reports	Share
Under 2	29	0.3%
2 to 11	113	1.1%
12 to 17	147	1.5%
18 to 44	1,578	15.8%
45 to 64	2,460	24.6%
65 to 74	1,118	11.2%
75 and over	718	7.2%
Age not given	3,823	38.3%

Sex of the patient in the reports that record Sluggishness
Sex	Reports	Share
Female	5,658	56.7%
Male	3,639	36.4%
Unknown or not given	689	6.9%

Age and sex are as the report gives them. 76.1% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Sluggishness: adverse event reports that record this term. https://reportedreactions.com/reaction/sluggishness/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Sluggishness mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page